Ming Lü
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 9
- Cancer-related molecular mechanisms research 5
- Immunology top 5%
- Immune cells in cancer 7
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms 3
- Oncology top 10%
- Drug Transport and Resistance Mechanisms 4
- Molecular Biology top 10%
- Epigenetics and DNA Methylation 3
- Hepatology top 10%
-
- Monoclonal and Polyclonal Antibodies Research 5
-
- Nanoplatforms for cancer theranostics 3
- Cited by
- Cancer ResearchImmunologyOncology
- Journals
- Acta Biochimica et Biophysica Sinica (4 papers)Journal of Translational Medicine (2 papers)Cell Metabolism (1 paper)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Ming Lü
38 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 90
- Cancer Research 553
- Immunology 622
- Oncology 449
- Molecular Biology 812
- Hepatology 81
Countries citing papers authored by Ming Lü
This map shows the geographic impact of Ming Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Lü more than expected).
Fields of papers citing papers by Ming Lü
This network shows the impact of papers produced by Ming Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Lü. The network helps show where Ming Lü may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ming Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 14 | |
| 4 | 2024 | 7 | |
| 5 | 2023 | 3 | |
| 6 | 2021 | 16 | |
| 7 | 2021 | 13 | |
| 8 | 2021 | 70 | |
| 9 | 2020 | 60 | |
| 10 | 2020 | 41 | |
| 11 | 2020 | 180 | |
| 12 | 2020 | 112 | |
| 13 | 2019 | 32 | |
| 14 | 2019 | 22 | |
| 15 | 2019 | 101 | |
| 16 | 2018 | 98 | |
| 17 | 2016 | 10 | |
| 18 | 2016 | 1 | |
| 19 | 2015 | 8 | |
| 20 | 1997 | 29 |
About Ming Lü
Ming Lü is a scholar working on Cancer Research, Immunology, Biotechnology, Oncology and Molecular Biology, having authored 40 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (9 papers), Immune cells in cancer (7 papers), Cancer-related molecular mechanisms research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Drug Transport and Resistance Mechanisms (4 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (3 papers), Nanoplatforms for cancer theranostics (3 papers) and Epigenetics and DNA Methylation (3 papers). The work is most often cited by research in Cancer Research (553 citations), Immunology (622 citations), Oncology (449 citations), Molecular Biology (812 citations) and Hepatology (81 citations). Ming Lü has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Lun–Xiu Qin, Hu‐Liang Jia, Wenwei Zhu, Jinhong Chen, Zhifei Lin, Lu Lu, Jubo Zhang, Qiongzhu Dong, Li Hua and Peishan Li. Their work appears in journals such as Acta Biochimica et Biophysica Sinica, Journal of Translational Medicine, Cell Metabolism, Scientific Reports and Neoplasia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.